請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/74504完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 華國泰(Kuo-Tai Hua) | |
| dc.contributor.author | Ke-Fan Pan | en |
| dc.contributor.author | 潘可梵 | zh_TW |
| dc.date.accessioned | 2021-06-17T08:39:33Z | - |
| dc.date.available | 2024-01-01 | |
| dc.date.copyright | 2021-02-23 | |
| dc.date.issued | 2021 | |
| dc.date.submitted | 2021-01-19 | |
| dc.identifier.citation | Anastas JN, Moon RT (2013) WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer 13: 11-26 Aoun F, Peltier A, van Velthoven R (2014) A comprehensive review of contemporary role of local treatment of the primary tumor and/or the metastases in metastatic prostate cancer. Biomed Res Int 2014: 501213 Armstrong AJ, Marengo MS, Oltean S, Kemeny G, Bitting RL, Turnbull JD, Herold CI, Marcom PK, George DJ, Garcia-Blanco MA (2011) Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. Mol Cancer Res 9: 997-1007 Arora A, Scholar EM (2005) Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 315: 971-9 Asally M, Yoneda Y (2005) Beta-catenin can act as a nuclear import receptor for its partner transcription factor, lymphocyte enhancer factor-1 (lef-1). Exp Cell Res 308: 357-63 Attard G, Parker C, Eeles RA, Schroder F, Tomlins SA, Tannock I, Drake CG, de Bono JS (2016) Prostate cancer. Lancet 387: 70-82 Bambury RM, Rathkopf DE (2016) Novel and next-generation androgen receptor-directed therapies for prostate cancer: Beyond abiraterone and enzalutamide. Urol Oncol 34: 348-55 Banerji U, O'Donnell A, Scurr M, Pacey S, Stapleton S, Asad Y, Simmons L, Maloney A, Raynaud F, Campbell M et al. (2005) Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 23: 4152-61 Bechard D, Gentina T, Delehedde M, Scherpereel A, Lyon M, Aumercier M, Vazeux R, Richet C, Degand P, Jude B et al. (2001a) Endocan is a novel chondroitin sulfate/dermatan sulfate proteoglycan that promotes hepatocyte growth factor/scatter factor mitogenic activity. J Biol Chem 276: 48341-9 Bechard D, Scherpereel A, Hammad H, Gentina T, Tsicopoulos A, Aumercier M, Pestel J, Dessaint JP, Tonnel AB, Lassalle P (2001b) Human endothelial-cell specific molecule-1 binds directly to the integrin CD11a/CD18 (LFA-1) and blocks binding to intercellular adhesion molecule-1. J Immunol 167: 3099-106 Beltran H, Yelensky R, Frampton GM, Park K, Downing SR, MacDonald TY, Jarosz M, Lipson D, Tagawa ST, Nanus DM et al. (2013) Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. Eur Urol 63: 920-6 Bhatt RI, Brown MD, Hart CA, Gilmore P, Ramani VA, George NJ, Clarke NW (2003) Novel method for the isolation and characterisation of the putative prostatic stem cell. Cytometry A 54: 89-99 Bisson I, Prowse DM (2009) WNT signaling regulates self-renewal and differentiation of prostate cancer cells with stem cell characteristics. Cell Res 19: 683-97 Brown MD, Gilmore PE, Hart CA, Samuel JD, Ramani VA, George NJ, Clarke NW (2007) Characterization of benign and malignant prostate epithelial Hoechst 33342 side populations. Prostate 67: 1384-96 Bui M, Reiter RE (1998) Stem cell genes in androgen-independent prostate cancer. Cancer Metastasis Rev 17: 391-9 Canesin G, Evans-Axelsson S, Hellsten R, Krzyzanowska A, Prasad CP, Bjartell A, Andersson T (2017) Treatment with the WNT5A-mimicking peptide Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model. PLoS One 12: e0184418 Carvalho FL, Simons BW, Eberhart CG, Berman DM (2014) Notch signaling in prostate cancer: a moving target. Prostate 74: 933-45 Chang AJ, Autio KA, Roach M, 3rd, Scher HI (2014) High-risk prostate cancer-classification and therapy. Nat Rev Clin Oncol 11: 308-23 Chauhan A, Tikoo A, Kapur AK, Singh M (2007) The taming of the cell penetrating domain of the HIV Tat: myths and realities. J Control Release 117: 148-62 Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL (2004a) Molecular determinants of resistance to antiandrogen therapy. Nat Med 10: 33-9 Chen CM, Lin CL, Chiou HL, Hsieh SC, Lin CL, Cheng CW, Hung CH, Tsai JP, Hsieh YH (2017) Loss of endothelial cell-specific molecule 1 promotes the tumorigenicity and metastasis of prostate cancer cells through regulation of the TIMP-1/MMP-9 expression. Oncotarget 8: 13886-13897 Chen D, Frezza M, Schmitt S, Kanwar J, Dou QP (2011) Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Curr Cancer Drug Targets 11: 239-53 Chen G, Shukeir N, Potti A, Sircar K, Aprikian A, Goltzman D, Rabbani SA (2004b) Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications. Cancer 101: 1345-56 Chen LY, Liu X, Wang SL, Qin CY (2010) Over-expression of the Endocan gene in endothelial cells from hepatocellular carcinoma is associated with angiogenesis and tumour invasion. J Int Med Res 38: 498-510 Chesire DR, Ewing CM, Sauvageot J, Bova GS, Isaacs WB (2000) Detection and analysis of beta-catenin mutations in prostate cancer. Prostate 45: 323-34 Chesire DR, Isaacs WB (2002) Ligand-dependent inhibition of beta-catenin/TCF signaling by androgen receptor. Oncogene 21: 8453-69 Ciarlo M, Benelli R, Barbieri O, Minghelli S, Barboro P, Balbi C, Ferrari N (2012) Regulation of neuroendocrine differentiation by AKT/hnRNPK/AR/beta-catenin signaling in prostate cancer cells. Int J Cancer 131: 582-90 Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ (2005) Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65: 10946-51 Colombel M, Symmans F, Gil S, O'Toole KM, Chopin D, Benson M, Olsson CA, Korsmeyer S, Buttyan R (1993) Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers. Am J Pathol 143: 390-400 Cookson MS, Roth BJ, Dahm P, Engstrom C, Freedland SJ, Hussain M, Lin DW, Lowrance WT, Murad MH, Oh WK et al. (2013) Castration-resistant prostate cancer: AUA Guideline. J Urol 190: 429-38 Cornelius A, Cortet-Rudelli C, Assaker R, Kerdraon O, Gevaert MH, Prevot V, Lassalle P, Trouillas J, Delehedde M, Maurage CA (2012) Endothelial expression of endocan is strongly associated with tumor progression in pituitary adenoma. Brain Pathol 22: 757-64 Craft N, Chhor C, Tran C, Belldegrun A, DeKernion J, Witte ON, Said J, Reiter RE, Sawyers CL (1999) Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. Cancer Res 59: 5030-6 Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW et al. (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351: 781-91 Cui D, Dai J, Keller JM, Mizokami A, Xia S, Keller ET (2015) Notch Pathway Inhibition Using PF-03084014, a gamma-Secretase Inhibitor (GSI), Enhances the Antitumor Effect of Docetaxel in Prostate Cancer. Clin Cancer Res 21: 4619-29 Cui J, Wang Y, Dong B, Qin L, Wang C, Zhou P, Wang X, Xu H, Xue W, Fang YX et al. (2018) Pharmacological inhibition of the Notch pathway enhances the efficacy of androgen deprivation therapy for prostate cancer. Int J Cancer 143: 645-656 Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G, Klocker H (1994) Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 54: 5474-8 Darash-Yahana M, Pikarsky E, Abramovitch R, Zeira E, Pal B, Karplus R, Beider K, Avniel S, Kasem S, Galun E et al. (2004) Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis. FASEB J 18: 1240-2 de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, Doyle GV, Terstappen LW, Pienta KJ, Raghavan D (2008) Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 14: 6302-9 Depontieu F, Grigoriu BD, Scherpereel A, Adam E, Delehedde M, Gosset P, Lassalle P (2008) Loss of Endocan tumorigenic properties after alternative splicing of exon 2. BMC Cancer 8: 14 Desai A, Yan Y, Gerson SL (2019) Concise Reviews: Cancer Stem Cell Targeted Therapies: Toward Clinical Success. Stem Cells Transl Med 8: 75-81 Du Q, Geller DA (2010) Cross-Regulation Between Wnt and NF-kappaB Signaling Pathways. For Immunopathol Dis Therap 1: 155-181 Dubrovska A, Kim S, Salamone RJ, Walker JR, Maira SM, Garcia-Echeverria C, Schultz PG, Reddy VA (2009) The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc Natl Acad Sci U S A 106: 268-73 Easwaran H, Tsai HC, Baylin SB (2014) Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. Mol Cell 54: 716-27 Edwards IJ (2012) Proteoglycans in prostate cancer. Nat Rev Urol 9: 196-206 Fagerberg L, Hallstrom BM, Oksvold P, Kampf C, Djureinovic D, Odeberg J, Habuka M, Tahmasebpoor S, Danielsson A, Edlund K et al. (2014) Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. Mol Cell Proteomics 13: 397-406 Feldman BJ, Feldman D (2001) The development of androgen-independent prostate cancer. Nat Rev Cancer 1: 34-45 Friedl A (2010) Proteoglycans: master modulators of paracrine fibroblast-carcinoma cell interactions. Semin Cell Dev Biol 21: 66-71 Gelmann EP (2002) Molecular biology of the androgen receptor. J Clin Oncol 20: 3001-15 Gerritsen ME, Tomlinson JE, Zlot C, Ziman M, Hwang S (2003) Using gene expression profiling to identify the molecular basis of the synergistic actions of hepatocyte growth factor and vascular endothelial growth factor in human endothelial cells. Br J Pharmacol 140: 595-610 Gioeli D, Ficarro SB, Kwiek JJ, Aaronson D, Hancock M, Catling AD, White FM, Christian RE, Settlage RE, Shabanowitz J et al. (2002) Androgen receptor phosphorylation. Regulation and identification of the phosphorylation sites. J Biol Chem 277: 29304-14 Gleave M, Miyake H (2005) Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancer. World J Urol 23: 38-46 Gonnissen A, Isebaert S, Haustermans K (2013) Hedgehog signaling in prostate cancer and its therapeutic implication. Int J Mol Sci 14: 13979-4007 Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, Quist MJ, Jing X, Lonigro RJ, Brenner JC et al. (2012) The mutational landscape of lethal castration-resistant prostate cancer. Nature 487: 239-43 Gregory CW, Johnson RT, Jr., Mohler JL, French FS, Wilson EM (2001) Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 61: 2892-8 Grem JL, Morrison G, Guo XD, Agnew E, Takimoto CH, Thomas R, Szabo E, Grochow L, Grollman F, Hamilton JM et al. (2005) Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. J Clin Oncol 23: 1885-93 Grigoriu BD, Depontieu F, Scherpereel A, Gourcerol D, Devos P, Ouatas T, Lafitte JJ, Copin MC, Tonnel AB, Lassalle P (2006) Endocan expression and relationship with survival in human non-small cell lung cancer. Clin Cancer Res 12: 4575-82 Gurney A, Axelrod F, Bond CJ, Cain J, Chartier C, Donigan L, Fischer M, Chaudhari A, Ji M, Kapoun AM et al. (2012) Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors. Proc Natl Acad Sci U S A 109: 11717-22 Harris KS, Kerr BA (2017) Prostate Cancer Stem Cell Markers Drive Progression, Therapeutic Resistance, and Bone Metastasis. Stem Cells Int 2017: 8629234 Hassell JR, Kimura JH, Hascall VC (1986) Proteoglycan core protein families. Annu Rev Biochem 55: 539-67 Heitz F, Morris MC, Divita G (2009) Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics. Br J Pharmacol 157: 195-206 Henderson BR, Fagotto F (2002) The ins and outs of APC and beta-catenin nuclear transport. EMBO Rep 3: 834-9 Herheliuk T, Perepelytsina O, Ugnivenko A, Ostapchenko L, Sydorenko M (2019) Investigation of multicellular tumor spheroids enriched for a cancer stem cell phenotype. Stem Cell Investig 6: 21 Hu WY, Hu DP, Xie L, Li Y, Majumdar S, Nonn L, Hu H, Shioda T, Prins GS (2017) Isolation and functional interrogation of adult human prostate epithelial stem cells at single cell resolution. Stem Cell Res 23: 1-12 Huang GW, Tao YM, Ding X (2009) Endocan expression correlated with poor survival in human hepatocellular carcinoma. Dig Dis Sci 54: 389-94 Hung MC, Link W (2011) Protein localization in disease and therapy. J Cell Sci 124: 3381-92 Iozzo RV (1998) Matrix proteoglycans: from molecular design to cellular function. Annu Rev Biochem 67: 609-52 Iozzo RV, Sanderson RD (2011) Proteoglycans in cancer biology, tumour microenvironment and angiogenesis. J Cell Mol Med 15: 1013-31 Isaacs JT (1999) The biology of hormone refractory prostate cancer. Why does it develop? Urol Clin North Am 26: 263-73 Ishiguro T, Ohata H, Sato A, Yamawaki K, Enomoto T, Okamoto K (2017) Tumor-derived spheroids: Relevance to cancer stem cells and clinical applications. Cancer Sci 108: 283-289 Ito T, Grant L, Duckham BR, Ribbands AJ, Gater A (2018) Qualitative and Quantitative Assessment of Patient and Carer Experience of Chemotherapy (Docetaxel) in Combination with Androgen Deprivation Therapy (ADT) for the Treatment of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC). Adv Ther 35: 2186-2200 Jamieson C, Sharma M, Henderson BR (2014) Targeting the beta-catenin nuclear transport pathway in cancer. Semin Cancer Biol 27: 20-9 Jehle K, Cato L, Neeb A, Muhle-Goll C, Jung N, Smith EW, Buzon V, Carbo LR, Estebanez-Perpina E, Schmitz K et al. (2014) Coregulator control of androgen receptor action by a novel nuclear receptor-binding motif. J Biol Chem 289: 8839-51 Jeong CW, Kang M, Il Jung S, Kim TH, Park SW, Joung JY, Jeon SS, Hong JH, Lee JY, Chung BH et al. (2019) Importance of androgen-deprivation therapy during enzalutamide treatment in men with metastatic castration-resistant prostate cancer following chemotherapy: results from retrospective, multicenter data. Prostate Cancer Prostatic Dis 22: 150-158 Jin R, Yi Y, Yull FE, Blackwell TS, Clark PE, Koyama T, Smith JA, Jr., Matusik RJ (2014) NF-kappaB gene signature predicts prostate cancer progression. Cancer Res 74: 2763-72 Jung Y, Cackowski FC, Yumoto K, Decker AM, Wang J, Kim JK, Lee E, Wang Y, Chung JS, Gursky AM et al. (2018) CXCL12gamma Promotes Metastatic Castration-Resistant Prostate Cancer by Inducing Cancer Stem Cell and Neuroendocrine Phenotypes. Cancer Res 78: 2026-2039 Kali A, Shetty KS (2014) Endocan: a novel circulating proteoglycan. Indian J Pharmacol 46: 579-83 Kaltschmidt C, Banz-Jansen C, Benhidjeb T, Beshay M, Forster C, Greiner J, Hamelmann E, Jorch N, Mertzlufft F, Pfitzenmaier J et al. (2019) A Role for NF-kappaB in Organ Specific Cancer and Cancer Stem Cells. Cancers (Basel) 11 Kang YH, Ji NY, Han SR, Lee CI, Kim JW, Yeom YI, Kim YH, Chun HK, Kim JW, Chung JW et al. (2012) ESM-1 regulates cell growth and metastatic process through activation of NF-kappaB in colorectal cancer. Cell Signal 24: 1940-9 Karhadkar SS, Bova GS, Abdallah N, Dhara S, Gardner D, Maitra A, Isaacs JT, Berman DM, Beachy PA (2004) Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature 431: 707-12 Kasper S (2009) Identification, characterization, and biological relevance of prostate cancer stem cells from clinical specimens. Urol Oncol 27: 301-3 Kerr BA, Miocinovic R, Smith AK, West XZ, Watts KE, Alzayed AW, Klink JC, Mir MC, Sturey T, Hansel DE et al. (2015) CD117(+) cells in the circulation are predictive of advanced prostate cancer. Oncotarget 6: 1889-97 Kim KH, Lee HH, Yoon YE, Na JC, Kim SY, Cho YI, Hong SJ, Han WK (2018) Clinical validation of serum endocan (ESM-1) as a potential biomarker in patients with renal cell carcinoma. Oncotarget 9: 662-667 Kim YH, Han ME, Oh SO (2017) The molecular mechanism for nuclear transport and its application. Anat Cell Biol 50: 77-85 Kjellen L, Lindahl U (1991) Proteoglycans: structures and interactions. Annu Rev Biochem 60: 443-75 Kozlowski JM, Fidler IJ, Campbell D, Xu ZL, Kaighn ME, Hart IR (1984) Metastatic behavior of human tumor cell lines grown in the nude mouse. Cancer Res 44: 3522-9 Kretzschmar K, Cottle DL, Schweiger PJ, Watt FM (2015) The Androgen Receptor Antagonizes Wnt/beta-Catenin Signaling in Epidermal Stem Cells. J Invest Dermatol 135: 2753-2763 Krieghoff E, Behrens J, Mayr B (2006) Nucleo-cytoplasmic distribution of beta-catenin is regulated by retention. J Cell Sci 119: 1453-63 Krishnamurthy N, Kurzrock R (2018) Targeting the Wnt/beta-catenin pathway in cancer: Update on effectors and inhibitors. Cancer Treat Rev 62: 50-60 Kypta RM, Waxman J (2012) Wnt/beta-catenin signalling in prostate cancer. Nat Rev Urol 9: 418-28 Labrie F, Dupont A, Belanger A, St-Arnaud R, Giguere M, Lacourciere Y, Emond J, Monfette G (1986) Treatment of prostate cancer with gonadotropin-releasing hormone agonists. Endocr Rev 7: 67-74 Lai CY, Chen CM, Hsu WH, Hsieh YH, Liu CJ (2017) Overexpression of Endothelial Cell-Specific Molecule 1 Correlates with Gleason Score and Expression of Androgen Receptor in Prostate Carcinoma. Int J Med Sci 14: 1263-1267 Laloglu E, Kumtepe Y, Aksoy H, Topdagi Yilmaz EP (2017) Serum endocan levels in endometrial and ovarian cancers. J Clin Lab Anal 31 Lassalle P, Molet S, Janin A, Heyden JV, Tavernier J, Fiers W, Devos R, Tonnel AB (1996) ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines. J Biol Chem 271: 20458-64 Lauth M, Bergstrom A, Shimokawa T, Toftgard R (2007) Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists. Proc Natl Acad Sci U S A 104: 8455-60 Lee E, Ha S, Logan SK (2015) Divergent Androgen Receptor and Beta-Catenin Signaling in Prostate Cancer Cells. PLoS One 10: e0141589 Lee HG, Choi HY, Bae JS (2014) Endocan as a potential diagnostic or prognostic biomarker for chronic kidney disease. Kidney Int 86: 1079-81 Leroy X, Aubert S, Zini L, Franquet H, Kervoaze G, Villers A, Delehedde M, Copin MC, Lassalle P (2010) Vascular endocan (ESM-1) is markedly overexpressed in clear cell renal cell carcinoma. Histopathology 56: 180-7 Li C, Geng H, Ji L, Ma X, Yin Q, Xiong H (2019) ESM-1: A Novel Tumor Biomaker and its Research Advances. Anticancer Agents Med Chem 19: 1687-1694 Li Z, Bishop AC, Alyamani M, Garcia JA, Dreicer R, Bunch D, Liu J, Upadhyay SK, Auchus RJ, Sharifi N (2015) Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer. Nature 523: 347-51 Lindahl U, Kusche-Gullberg M, Kjellen L (1998) Regulated diversity of heparan sulfate. J Biol Chem 273: 24979-82 Liu C, Liu R, Zhang D, Deng Q, Liu B, Chao HP, Rycaj K, Takata Y, Lin K, Lu Y et al. (2017) MicroRNA-141 suppresses prostate cancer stem cells and metastasis by targeting a cohort of pro-metastasis genes. Nat Commun 8: 14270 Liu H, Yin J, Wang H, Jiang G, Deng M, Zhang G, Bu X, Cai S, Du J, He Z (2015) FOXO3a modulates WNT/beta-catenin signaling and suppresses epithelial-to-mesenchymal transition in prostate cancer cells. Cell Signal 27: 510-8 Liu N, Zhang LH, Du H, Hu Y, Zhang GG, Wang XH, Li JY, Ji JF (2010) Overexpression of endothelial cell specific molecule-1 (ESM-1) in gastric cancer. Ann Surg Oncol 17: 2628-39 Logothetis CJ, Gallick GE, Maity SN, Kim J, Aparicio A, Efstathiou E, Lin SH (2013) Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer. Cancer Discov 3: 849-61 Lu Y, Xie S, Zhang W, Zhang C, Gao C, Sun Q, Cai Y, Xu Z, Xiao M, Xu Y et al. (2017) Twa1/Gid8 is a beta-catenin nuclear retention factor in Wnt signaling and colorectal tumorigenesis. Cell Res 27: 1422-1440 Ma B, Fey M, Hottiger MO (2015) WNT/beta-catenin signaling inhibits CBP-mediated RelA acetylation and expression of proinflammatory NF-kappaB target genes. J Cell Sci 128: 2430-6 Ma B, Hottiger MO (2016) Crosstalk between Wnt/beta-Catenin and NF-kappaB Signaling Pathway during Inflammation. Front Immunol 7: 378 Madueke I, Hu WY, Hu D, Swanson SM, Vander Griend D, Abern M, Prins GS (2019) The role of WNT10B in normal prostate gland development and prostate cancer. Prostate 79: 1692-1704 Makridakis N, Ross RK, Pike MC, Chang L, Stanczyk FZ, Kolonel LN, Shi CY, Yu MC, Henderson BE, Reichardt JK (1997) A prevalent missense substitution that modulates activity of prostatic steroid 5alpha-reductase. Cancer Res 57: 1020-2 Maurage CA, Adam E, Mineo JF, Sarrazin S, Debunne M, Siminski RM, Baroncini M, Lassalle P, Blond S, Delehedde M (2009) Endocan expression and localization in human glioblastomas. J Neuropathol Exp Neurol 68: 633-41 McCarty MF (2004) Targeting multiple signaling pathways as a strategy for managing prostate cancer: multifocal signal modulation therapy. Integr Cancer Ther 3: 349-80 McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT, Tu SM, Campbell ML (1992) Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52: 6940-4 Moltzahn F, Thalmann GN (2013) Cancer stem cells in prostate cancer. Transl Androl Urol 2: 242-53 Monaghan AE, McEwan IJ (2016) A sting in the tail: the N-terminal domain of the androgen receptor as a drug target. Asian J Androl 18: 687-94 Mulholland DJ, Cheng H, Reid K, Rennie PS, Nelson CC (2002) The androgen receptor can promote beta-catenin nuclear translocation independently of adenomatous polyposis coli. J Biol Chem 277: 17933-43 Munuganti RS, Hassona MD, Leblanc E, Frewin K, Singh K, Ma D, Ban F, Hsing M, Adomat H, Lallous N et al. (2014) Identification of a potent antiandrogen that targets the BF3 site of the androgen receptor and inhibits enzalutamide-resistant prostate cancer. Chem Biol 21: 1476-85 Murillo-Garzon V, Kypta R (2017) WNT signalling in prostate cancer. Nat Rev Urol 14: 683-696 Myung JK, Banuelos CA, Fernandez JG, Mawji NR, Wang J, Tien AH, Yang YC, Tavakoli I, Haile S, Watt K et al. (2013) An androgen receptor N-terminal domain antagonist for treating prostate cancer. J Clin Invest 123: 2948-60 Nanta R, Kumar D, Meeker D, Rodova M, Van Veldhuizen PJ, Shankar S, Srivastava RK (2013) NVP-LDE-225 (Erismodegib) inhibits epithelial-mesenchymal transition and human prostate cancer stem cell growth in NOD/SCID IL2Rgamma null mice by regulating Bmi-1 and microRNA-128. Oncogenesis 2: e42 Nelson WG, De Marzo AM, Isaacs WB (2003) Prostate cancer. N Engl J Med 349: 366-81 Nguyen DP, Li J, Yadav SS, Tewari AK (2014) Recent insights into NF-kappaB signalling pathways and the link between inflammation and prostate cancer. BJU Int 114: 168-76 Ni J, Cozzi P, Hao J, Duan W, Graham P, Kearsley J, Li Y (2014) Cancer stem cells in prostate cancer chemoresistance. Curr Cancer Drug Targets 14: 225-40 Patel R, Brzezinska EA, Repiscak P, Ahmad I, Mui E, Gao M, Blomme A, Harle V, Tan EH, Malviya G et al. (2020) Activation of beta-Catenin Cooperates with Loss of Pten to Drive AR-Independent Castration-Resistant Prostate Cancer. Cancer Res 80: 576-590 Pattabiraman DR, Weinberg RA (2014) Tackling the cancer stem cells - what challenges do they pose? Nat Rev Drug Discov 13: 497-512 Peng YM, Zheng JB, Zhou YB, Li J (2013) Characterization of a novel curcumin analog P1 as potent inhibitor of the NF-kappaB signaling pathway with distinct mechanisms. Acta Pharmacol Sin 34: 939-50 Pienta KJ, Smith DC (2005) Advances in prostate cancer chemotherapy: a new era begins. CA Cancer J Clin 55: 300-18; quiz 323-5 Rajasekhar VK, Studer L, Gerald W, Socci ND, Scher HI (2011) Tumour-initiating stem-like cells in human prostate cancer exhibit increased NF-kappaB signalling. Nat Commun 2: 162 Ravindranath A, Yuen HF, Chan KK, Grills C, Fennell DA, Lappin TR, El-Tanani M (2011) Wnt-beta-catenin-Tcf-4 signalling-modulated invasiveness is dependent on osteopontin expression in breast cancer. Br J Cancer 105: 542-51 Rebollo J, Geliebter J, Reyes N (2017) ESM-1 siRNA Knockdown Decreased Migration and Expression of CXCL3 in Prostate Cancer Cells. Int J Biomed Sci 13: 35-42 Reya T, Clevers H (2005) Wnt signalling in stem cells and cancer. Nature 434: 843-50 Rimkus TK, Carpenter RL, Qasem S, Chan M, Lo HW (2016) Targeting the Sonic Hedgehog Signaling Pathway: Review of Smoothened and GLI Inhibitors. Cancers (Basel) 8 Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G et al. (2015) Integrative clinical genomics of advanced prostate cancer. Cell 161: 1215-1228 Rocha SF, Schiller M, Jing D, Li H, Butz S, Vestweber D, Biljes D, Drexler HC, Nieminen-Kelha M, Vajkoczy P et al. (2014) Esm1 modulates endothelial tip cell behavior and vascular permeability by enhancing VEGF bioavailability. Circ Res 115: 581-90 Roudnicky F, Poyet C, Wild P, Krampitz S, Negrini F, Huggenberger R, Rogler A, Stohr R, Hartmann A, Provenzano M et al. (2013) Endocan is upregulated on tumor vessels in invasive bladder cancer where it mediates VEGF-A-induced angiogenesis. Cancer Res 73: 1097-106 Ryan CJ, Dutta S, Kelly WK, Russell C, Small EJ, Morris MJ, Taplin ME, Halabi S (2019) Androgen decline and survival during docetaxel therapy in metastatic castration resistant prostate cancer (mCRPC). Prostate Cancer Prostatic Dis Rybak AP, Ingram AJ, Tang D (2013) Propagation of human prostate cancer stem-like cells occurs through EGFR-mediated ERK activation. PLoS One 8: e61716 Schepeler T, Holm A, Halvey P, Nordentoft I, Lamy P, Riising EM, Christensen LL, Thorsen K, Liebler DC, Helin K et al. (2012) Attenuation of the beta-catenin/TCF4 complex in colorectal cancer cells induces several growth-suppressive microRNAs that target cancer promoting genes. Oncogene 31: 2750-60 Scherpereel A, Gentina T, Grigoriu B, Senechal S, Janin A, Tsicopoulos A, Plenat F, Bechard D, Tonnel AB, Lassalle P (2003) Overexpression of endocan induces tumor formation. Cancer Res 63: 6084-9 Schneider JA, Logan SK (2018) Revisiting the role of Wnt/beta-catenin signaling in prostate cancer. Mol Cell Endocrinol 462: 3-8 Schultz NM, Flanders SC, Wilson S, Brown BA, Song Y, Yang H, Lechpammer S, Kassabian V (2018) Treatment Duration, Healthcare Resource Utilization, and Costs Among Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate: A Retrospective Claims Analysis. Adv Ther 35: 1639-1655 Schwitalla S, Fingerle AA, Cammareri P, Nebelsiek T, Goktuna SI, Ziegler PK, Canli O, Heijmans J, Huels DJ, Moreaux G et al. (2013) Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties. Cell 152: 25-38 Shang S, Hua F, Hu ZW (2017) The regulation of beta-catenin activity and function in cancer: therapeutic opportunities. Oncotarget 8: 33972-33989 Sharma M, Jamieson C, Johnson M, Molloy MP, Henderson BR (2012) Specific armadillo repeat sequences facilitate beta-catenin nuclear transport in live cells via direct binding to nucleoporins Nup62, Nup153, and RanBP2/Nup358. J Biol Chem 287: 819-31 Sheikh A, Niazi AK, Ahmed MZ, Iqbal B, Anwer SM, Khan HH (2014) The role of Wnt signaling pathway in carcinogenesis and implications for anticancer therapeutics. Hered Cancer Clin Pract 12: 13 Shukla S, Ohnuma S, Ambudkar SV (2011) Improving cancer chemotherapy with modulators of ABC drug transporters. Curr Drug Targets 12: 621-30 Song LN, Herrell R, Byers S, Shah S, Wilson EM, Gelmann EP (2003) Beta-catenin binds to the activation function 2 region of the androgen receptor and modulates the effects of the N-terminal domain and TIF2 on ligand-dependent transcription. Mol Cell Biol 23: 1674-87 Sorensen S, Borgesen SE, Rohde K, Rasmusson B, Bach F, Boge-Rasmussen T, Stjernholm P, Larsen BH, Agerlin N, Gjerris F et al. (1990) Metastatic epidural spinal cord compression. Results of treatment and survival. Cancer 65: 1502-8 Steeg PS (2016) Targeting metastasis. Nat Rev Cancer 16: 201-18 Suhovskih AV, Mostovich LA, Kunin IS, Boboev MM, Nepomnyashchikh GI, Aidagulova SV, Grigorieva EV (2013) Proteoglycan expression in normal human prostate tissue and prostate cancer. ISRN Oncol 2013: 680136 Sun S, Sprenger CC, Vessella RL, Haugk K, Soriano K, Mostaghel EA, Page ST, Coleman IM, Nguyen HM, Sun H et al. (2010) Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest 120: 2715-30 Takebe N, Harris PJ, Warren RQ, Ivy SP (2011) Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol 8: 97-106 Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I et al. (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502-12 Tapia MA, Gonzalez-Navarrete I, Dalmases A, Bosch M, Rodriguez-Fanjul V, Rolfe M, Ross JS, Mezquita J, Mezquita C, Bachs O et al. (2007) Inhibition of the canonical IKK/NF kappa B pathway sensitizes human cancer cells to doxorubicin. Cell Cycle 6: 2284-92 Taplin ME, Balk SP (2004) Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence. J Cell Biochem 91: 483-90 Theocharis AD, Skandalis SS, Tzanakakis GN, Karamanos NK (2010) Proteoglycans in health and disease: novel roles for proteoglycans in malignancy and their pharmacological targeting. FEBS J 277: 3904-23 Tolcher AW, Chi K, Kuhn J, Gleave M, Patnaik A, Takimoto C, Schwartz G, Thompson I, Berg K, D'Aloisio S et al. (2005) A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer. Clin Cancer Res 11: 3854-61 Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A et al. (2009) Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324: 787-90 Truica CI, Byers S, Gelmann EP (2000) Beta-catenin affects androgen receptor transcriptional activity and ligand specificity. Cancer Res 60: 4709-13 Tsai CH, Tzeng SF, Chao TK, Tsai CY, Yang YC, Lee MT, Hwang JJ, Chou YC, Tsai MH, Cha TL et al. (2016) Metastatic Progression of Prostate Cancer Is Mediated by Autonomous Binding of Galectin-4-O-Glycan to Cancer Cells. Cancer Res 76: 5756-5767 Veldscholte J, Berrevoets CA, Ris-Stalpers C, Kuiper GG, Jenster G, Trapman J, Brinkmann AO, Mulder E (1992) The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens. J Steroid Biochem Mol Biol 41: 665-9 Visvader JE, Lindeman GJ (2008) Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 8: 755-68 Visvader JE, Lindeman GJ (2012) Cancer stem cells: current status and evolving complexities. Cell Stem Cell 10: 717-728 Voeller HJ, Truica CI, Gelmann EP (1998) Beta-catenin mutations in human prostate cancer. Cancer Res 58: 2520-3 Wan X, Liu J, Lu JF, Tzelepi V, Yang J, Starbuck MW, Diao L, Wang J, Efstathiou E, Vazquez ES et al. (2012) Activation of beta-catenin signaling in androgen receptor-negative prostate cancer cells. Clin Cancer Res 18: 726-36 Wang X, Li S (2014) Protein mislocalization: mechanisms, functions and clinical applications in cancer. Biochim Biophys Acta 1846: 13-25 Wang XD, Shou J, Wong P, French DM, Gao WQ (2004) Notch1-expressing cells are indispensable for prostatic branching morphogenesis during development and re-growth following castration and androgen replacement. J Biol Chem 279: 24733-44 Wilding G, Chen M, Gelmann EP (1989) Aberrant response in vitro of hormone-responsive prostate cancer cells to antiandrogens. Prostate 14: 103-15 Xu W, Kimelman D (2007) Mechanistic insights from structural studies of beta-catenin and its binding partners. J Cell Sci 120: 3337-44 Yang J, Yang Q, Yu S, Zhang X (2015) Endocan: A new marker for cancer and a target for cancer therapy. Biomed Rep 3: 279-283 Yang T, Rycaj K (2015) Targeted therapy against cancer stem cells. Oncol Lett 10: 27-33 Yang YC, Pan KF, Lee WJ, Chang JH | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/74504 | - |
| dc.description.abstract | 雖然Wnt/β-catenin訊息傳遞路徑的活化常見於晚期攝護腺癌中，然而其訊息傳遞路徑上的相關基因突變在攝護腺癌中卻十分少見，因此這條訊息傳遞路徑在攝護腺癌中可能存在未知的調控機轉。在此篇研究中，我們發現一種分泌型多醣蛋白Endothelial cell-specific molecule 1 (ESM1)的表現量與攝護腺癌的進程及轉移具高度相關性，且ESM1表現較高的病人其總體存活率較低。ESM1可透過活化Wnt/β-catenin訊息傳遞路徑調控癌細胞的幹性以促進攝護腺癌的進程。此外我們也發現ESM1在侵犯程度較高的攝護腺癌細胞核內高度表現，而這群在核內的ESM1相較於其原始的分泌狀態更可支持攝護腺癌幹性。透過與β-catenin的armadillo (ARM) repeat domain結合，ESM1可幫助穩定β-catenin及其cofactor T-cell factor 4 (TCF4)的聚合體，進而促進Wnt/β-catenin訊息傳遞路徑持續地活化。同時，活化的β-catenin也會幫助ESM1進入細胞核內，進一步促使ESM1/β-catenin/TCF4聚合體於核內停留並活化下游調控分子。我們的研究證實了核內的ESM1在攝護腺癌轉移過程的關鍵調控角色，可望成為一新穎的預後生物標記及藥物標靶。 | zh_TW |
| dc.description.abstract | Wnt/β-catenin signaling is frequently activated in advanced prostate cancer and contributes to therapy resistance and metastasis. However, activating mutations in the Wnt/β-catenin pathway are not common in prostate cancer, suggesting alternative regulations may exist. Here we report that the expression of endothelial cell-specific molecule 1 (ESM1), a secretory proteoglycan, is positively associated with prostate cancer stemness and progression by promoting Wnt/β-catenin signaling. Elevated ESM1 expression correlates with poor overall survival and metastasis. Accumulation of nuclear ESM1, instead of cytosolic or secretory ESM1, supports prostate cancer stemness by interacting with the ARM domain of β-catenin to stabilize β-catenin-TCF4 complex and facilitate the transactivation of Wnt/β-catenin signaling targets. Accordingly, activated β-catenin in turns mediates the nuclear entry of ESM1. Our results establish the significance of mislocalized ESM1 in driving metastasis in prostate cancer by coordinating the Wnt/β-catenin pathway, with implications for its potential use as a diagnostic or prognostic biomarker and as a candidate therapeutic target in prostate cancer. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-17T08:39:33Z (GMT). No. of bitstreams: 1 U0001-1901202116042800.pdf: 6163020 bytes, checksum: d06a5ec18114e0793743a67f82e4525b (MD5) Previous issue date: 2021 | en |
| dc.description.tableofcontents | 口試委員會審定書 致謝 Abbreviations II List of Figures VI List of Tables VIII 中文摘要 IX Abstract X Introduction 1 Materials and Methods 21 Results 33 Discussion 52 Figures and Figure legends 67 Tables 115 References 119 Appendix 146 | |
| dc.language.iso | en | |
| dc.subject | 癌症幹性 | zh_TW |
| dc.subject | 腫瘤轉移 | zh_TW |
| dc.subject | cancer stemness | en |
| dc.subject | tumor metastasis | en |
| dc.title | 探討內皮細胞特異分子在攝護腺癌進程之角色 | zh_TW |
| dc.title | Evaluation of the Role of Endothelial Cell-specific Molecule 1 (ESM1) in the Progression of Prostate Cancer | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 109-1 | |
| dc.description.degree | 博士 | |
| dc.contributor.author-orcid | 0000-0002-0178-1772 | |
| dc.contributor.oralexamcommittee | 蕭宏昇(Michael Hsiao),簡銘賢(Ming-Hsien Chien),李明學(Ming-Shyue Lee),鄭朝文(Chao-Wen Cheng) | |
| dc.subject.keyword | 癌症幹性,腫瘤轉移, | zh_TW |
| dc.subject.keyword | cancer stemness,tumor metastasis, | en |
| dc.relation.page | 146 | |
| dc.identifier.doi | 10.6342/NTU202100093 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2021-01-20 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 毒理學研究所 | zh_TW |
| 顯示於系所單位： | 毒理學研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| U0001-1901202116042800.pdf 未授權公開取用 | 6.02 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。